Molecular Vision
2010; 16:2395-2401
<http://www.molvis.org/molvis/v16/a257> Received 8 September 2010 | Accepted 9 November 2010 | Published 16 November 2010
Molecular Vision
2010; 16:2395-2401
<http://www.molvis.org/molvis/v16/a257>
Received 8 September 2010 | Accepted 9 November 2010 | Published 16
November 2010
Mukesh Tanwar,1 Manoj Kumar,1 Bhagabat Nayak,2 Dhananjay Pathak,1 Namrata Sharma,2 Jeewan S. Titiyal,2 Rima Dada1
The first two authors contributed equally to the manuscript
1Laboratory For Molecular Reproduction and Genetics, Department of Anatomy, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India; 2Dr. R.P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India
Correspondence to: Dr. Rima Dada, Associate Professor, Lab. For Molecular Reproduction and Genetics, Department of Anatomy, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India-110029; Phone: +91-11-26546716; FAX: +91-11-26588663; email: rima_dada@rediffmail.com
Purpose: To screen the visual system homeobox 1 (VSX1) gene in keratoconus patients.
Methods: The enntire coding region of VSX1, including intron-exon boundaries were amplified in keratoconus cases (n=50) and controls (n=50). All sequences were analyzed against the ensemble sequence (ENSG00000100987) for VXS1.
Results: Sequencing analysis showed four alterations (p.A182A, p.R217H, p.P237P, and g.25059612C>T) in VSX1 of which g.25059612C>T (in intron 2) was found to be novel. Of these four, p.A182A and p.P237P were present in both cases as well as controls while p.R217H and g.25059612C>T were limited to cases only. All these changes were non-pathogenic.
Conclusions: In our study no pathogenic VSX1 mutation was identified. The role of VSX1 in the pathogenesis of keratoconus is still controversial. VSX1 mutations are responsible for a very small fraction of all observed keratoconus cases. The absence of pathogenic mutations in VSX1 in our patients indicates that other genetic loci like 13q32 as suggested by a recent study may be involved in the pathogenesis of this disorder.
Keratoconus (KTCN; OMIM 148300) is a bilateral, non-inflammatory, and progredient corneal ectasia [1]. There is no specific treatment for keratoconus except corneal transplantation. It has an estimated incidence between 1/500 to 1/2,000 persons throughout the world. The disease usually arises in the teens and stabilizes in the third and fourth decade of life [2]. It occurs with no ethnic or gender preponderance and causes significant visual impairment. Most cases of keratoconus are sporadic but some (5%–10%) have a positive family history [2,3]. In such cases both autosomal dominant and recessive patterns of inheritance have been documented [4-6]. The exact pathogenesis of keratoconus is still unknown. Genome-wide linkage analyses has identified several chromosomal loci and genes that may be associated with keratoconus [6-9]; however, some were eventually excluded [10,11] while for others a conclusive association with the disease is yet to be established. Mutations in the visual system homeobox 1 (VSX1) gene in keratoconus have been reported in different studies [12-15].
VSX1 is a member of the Vsx1 group of vertebrate paired-like homeodomain transcription factors. It has been localized to human chromosome 20p11-q11. Initially VSX1 was chosen for screening mutations in posterior polymorphous corneal dystrophy (PPCD) and keratoconus [8]. VSX1 is considered important in ocular development and is particularly involved in the developing cornea. Expression in human was demonstrated in embryonic craniofacial, adult corneal, and adult retinal cDNA libraries [16]. VSX1 mRNA has been found in the outer tier of the inner nuclear layer of the human retina and the cornea [17]. Mutations in this gene are also associated with posterior polymorphous dystrophy. VSX1 is highly conserved across many species [18-20]. Several mutations, such as p.D144E, p.G160D, p.P247R, p.L159M, p.R166W, and p.H244R have been reported by various groups [14,17,21] but a definite pathogenic role of these mutations in keratoconus is not yet established. In this study we present the results of VSX1 gene analysis in 50 keratoconus patients and controls from north India.
The research followed the tenets of the Declaration of Helsinki in the treatment of the subject reported herein. The study was approved by institutional review board (IRB # IRB00006862) of the All India Institute of Medical Sciences (AIIMS) and all participants gave their written informed consent. A total of fifty keratoconus patients (Table 1) presented (during April 2009 to April 2010) at the Dr. R. P. Centre for Ophthalmic Sciences (AIIMS, New Delhi, India) were enrolled in this study. Clinical evaluation involved Ultrasonic Pachymetry, videokeratography (VKG), Orbscan, visual testing, fundoscopy, slitlamp-biomicroscopy, and retinoscopy. Of these patients, 29 were males and 21 were females. The mean age of presentation was 18.2 years. Diagnosis of keratoconus involved the presence of characteristic topographic features, such as inferior or central corneal steepening, or an asymmetric bowtie pattern with skewing of the radial axes, and the presence of one or more of the following characteristic clinical features in one or both eyes: conical corneal deformation, munsen sign, corneal stromal thinning, a Fleischer ring or Vogt striae. All cases were sporadic without any family history.
All keratoconus cases secondary to causes like trauma, surgery, Ehlers Danlos syndrome, Osteogenesis Imperfecta, and pellucid marginal degeneration were excluded from the study.
After informed consent, detailed personal, medical and occupational history was collected and a family tree up to three generations was drawn. Fifty ethnically matched normal individuals without any ocular disorder were enrolled as controls. Health information was obtained from controls through the questionnaire; all underwent ophthalmological examination and blood sample (5 ml) was collected in EDTA (EDTA) vacutainers (Greiner Bio-One GmbH, Frickenhausen, Germany) from patients and controls for DNA extraction. DNA was extracted from whole blood samples of all patients and controls using the phenol-chloroform method.
All the coding regions of VSX1 including exon-intron junctions were amplified using a set of five oligonucleotide primers (Table 2). Each reaction was performed in a 25 µl mixture containing 0.2 µM each primer, 0.5 U Taq DNA polymerase (Biogene, New Delhi, India), 2.5 µl 10× PCR buffer (Biogene) with 2.5 mM MgCl2, and approximately 100 ng genomic DNA. Thermal cycling was performed in a thermal cycler (My Cycler; Biorad, Gurgaon, India) under the following conditions: initial denaturation for 3 min at 95 °C; 35 cycles of 94 °C for 30 s, 55 0-60 °C for 45 s, 72 °C for 60 s; and a final extension for 10 min at 72 °C.
All PCR products were analyzed on 1.8% agarose gel stained with ethidium-bromide (EtBr; 10 mg/ml). Agarose gels were analyzed using gel documentation system (Applied Biosystems, Carlsbad, CA). Amplified PCR products were purified using gel/PCR DNA fragments extraction kit (DF100; Geneaid Biotech Ltd., Sijhih City Taiwan). The purified PCR products were sent for sequencing at MCLAB (Molecular Cloning Laboratories, South San Francisco, CA)
Nucleotide sequences were compared with the VSX1ensembl reference sequence.
Two homology based programs PolyPhen (Polymorphism Phenotyping) and SIFT (Sorting Intolerant From Tolerant) analysis tool were used to predict the functional impact of missense changes identified in this study.
PolyPhen structurally analyzes an amino acid polymorphism and predicts whether that amino acid change is likely to be deleterious to protein function [22,23]. The prediction is based on the position-specific independent counts (PSIC) score derived from multiple sequence alignments of observations. PolyPhen scores of >2.0 indicate the polymorphism is probably damaging to protein function. Scores of 1.5–2.0 are possibly damaging, and scores of <1.5 are likely benign.
SIFT is a sequence homology-based tool that sorts intolerant from tolerant amino acid substitutions and predicts whether an amino acid substitution in a protein will have a phenotypic effect [24,25]. SIFT is based on the premise that protein evolution is correlated with protein function. Positions important for function should be conserved in an alignment of the protein family, whereas unimportant positions should appear diverse in an alignment. Positions with normalized probabilities less than 0.05 are predicted to be deleterious and, those greater than or equal to 0.05 are predicted to be tolerated.
We have also used improved Splice Site predictor tool [26] for prediction the effect of an intronic nucleotide change on splicing.
DNA sequencing analysis of 50 patients and 50 controls revealed a total of four nucleotide changes (Table 3) of which one was novel and 3 have been previously reported. Details of these changes are given below.
In this mutation a single nucleotide adenine (A) was replaced by guanine (G) at g.25059546 (rs12480307); c.546; codon 182 resulted in codon change GCA>GCG resulting in synonymous change p.ala182ala (p.A182A; Figure 1). This change was present as homozygous change in 25 cases and 29 controls.
In this mutation a single nucleotide thymine (T) was replaced by adenine at position g.25059442 (rs6138482); cDNA position c.650; codon 217. This change resulted in a codon change from CGC>CAC resulting in non-synonymous change p.arg217his (p.R217H; Figure 2) in protein. This change was present in only one case and was homozygous but was absent in controls.
In this mutation a single nucleotide T was replaced by A at position g.25059381 (rs56157240); c.711; codon 237 resulted in a codon change CCT>CCA which predicts a synonymous change p.pro237pro (p.P237P; Figure 3). This change was present in 18/50 cases (7 were homozygous and 11 were heterozygous) being also present in 14/50 controls (9 were homozygous and 5 were heterozygous).
A novel single nucleotide change C>T at g.25059612 (Figure 4) was present in three cases but absent in controls. Alteration is located in 2nd intron (IVS3–24C>T). This change was registered at GenBank with accession number GU471016.
PolyPhen and SIFT analysis of p.R217H showed that it is non-pathogenic (SIFT score is >0.05 and PSIC score is <1.5).
Improved splice site predictor tool analysis of g.25059612C>T showed that this location (g.25059612) is not present at splice site and may not create splicing error in VSX1 mRNA. Conclusively, no pathogenic change was identified in our patients.
In this study we analyzed VSX1 in 50 unrelated keratoconus patients and controls from north India. In our patient’s, males were affected more than females. Mutations in VSX1 gene have been identified in association with keratoconus [12,14,15,17,21]. Human VSX1 is a member of the CVC domain containing paired-like class of homeoproteins. VSX1 expression in humans was detected in embryonic craniofacial, adult retinal, and adult corneal tissues [17,27]. The role of VSX1 in keratoconus is still ambiguous. Previous studies have shown that the pathogenesis of keratoconus is very complex and several genes and gene environmental interactions play a critical role in disease prognosis. In fact, VSX1 may have a pleiotropic action among the tissues of the cornea leading to keratoconus in some cases as observed for the transforming growth factor (TGFBI) gene; which causes four distinct autosomal dominant corneal diseases [28].
In this study, four sequence variations were detected of which 3 have been previously reported [15,20] and one was novel. SIFT and PolyPhen analysis of p.217H showed that it to be a non-pathogenic change. Similar findings have already been reported in European population [15].
The VSXI variants reported in various studies include p.L17P, p.D144E, p.N151S, p.L159M, p.G160V, p.G160D, p.R166W, p.Q175H, p.H244R, and p.P247R [12-15,17,21]. Some of these were initially reported to be pathogenic but their pathogenicity could not be confirmed as some of these variants were observed in unaffected individuals also. He’on and associates [14] identified a compound heterozygous change with p.P247R and p.G160D and reported p.G160D to be pathogenic and p.P247R to be nonpathogenic. Another study reported p.P247R as a pathogenic change because it was found to be co-segregating with keratoconus. Similarly, p.D144E mutation was initially reported as pathogenic [20,21,] but subsequent studies identified its presence in unaffected individuals and suggested this to be a non-pathogenic polymorphism [29,30]. The variants p.R166W, p.H244R, and p.L159M have been identified in keratoconus patients but these changes did not segregate with the disease phenotype in their family members and hence were not considered sufficiently significant to support a pathogenic role in keratoconus [31]. Similarly, variants p.G160V and p.N151S have been identified in patients from the Korean population [12] but these changes have not been reported in other populations.
In a recent study (2009) from India, VSX1 was screened in 66 keratoconus cases and a potentially pathogenic change (p.Q175H) was identified in one case only [13]. In this study, the second from India, no pathogenic change was indentified in VSX1. Similar results have been published recently [29,32,33]. So lack of possibly pathogenic changes in VSX1 gene in keratoconus patients suggests that mutations of VSX1 could only be responsible for a very small fraction of all observed cases and need to be investigated in different populations. This also suggests that other genetic loci like 13q32 as suggested by Gajecka et al. [34] may be involved in the pathogenesis of keratoconus.
The authors would like to thank the families of the patients for their co-operation. The author Mukesh Tanwar thanks University Grants Commission (UGC) Govt. of India and Manoj Kumar thanks Indian Council of Medical Research (ICMR) for providing Senior Research Fellowship (SRF).